| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Mitogen-activated protein kinase 13 |
|---|
| Ligand | BDBM50326053 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_655503 (CHEMBL1244547) |
|---|
| Kd | >10000±n/a nM |
|---|
| Citation |  Zarrinkar, PP; Gunawardane, RN; Cramer, MD; Gardner, MF; Brigham, D; Belli, B; Karaman, MW; Pratz, KW; Pallares, G; Chao, Q; Sprankle, KG; Patel, HK; Levis, M; Armstrong, RC; James, J; Bhagwat, SS AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood114:2984-92 (2009) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Mitogen-activated protein kinase 13 |
|---|
| Name: | Mitogen-activated protein kinase 13 |
|---|
| Synonyms: | MAP kinase p38 delta | MAPK13 | MK13_HUMAN | Mitogen-activated protein kinase 13 | Mitogen-activated protein kinase 13 (MAPK13) | Mitogen-activated protein kinase p38 | Mitogen-activated protein kinase p38 delta | PRKM13 | SAPK4 | Stress-activated protein kinase 4 | p38 delta/gamma |
|---|
| Type: | Enzyme |
|---|
| Mol. Mass.: | 42097.16 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | O15264 |
|---|
| Residue: | 365 |
|---|
| Sequence: | MSLIRKKGFYKQDVNKTAWELPKTYVSPTHVGSGAYGSVCSAIDKRSGEKVAIKKLSRPF
QSEIFAKRAYRELLLLKHMQHENVIGLLDVFTPASSLRNFYDFYLVMPFMQTDLQKIMGM
EFSEEKIQYLVYQMLKGLKYIHSAGVVHRDLKPGNLAVNEDCELKILDFGLARHADAEMT
GYVVTRWYRAPEVILSWMHYNQTVDIWSVGCIMAEMLTGKTLFKGKDYLDQLTQILKVTG
VPGTEFVQKLNDKAAKSYIQSLPQTPRKDFTQLFPRASPQAADLLEKMLELDVDKRLTAA
QALTHPFFEPFRDPEEETEAQQPFDDSLEHEKLTVDEWKQHIYKEIVNFSPIARKDSRRR
SGMKL
|
|
|
|---|
| BDBM50326053 |
|---|
| n/a |
|---|
| Name | BDBM50326053 |
|---|
| Synonyms: | CHEMBL608533 | PKC-412 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C35H30N4O4 |
|---|
| Mol. Mass. | 570.6371 |
|---|
| SMILES | CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1 |r| |
|---|
| Structure | 
|
|---|
Search and Browse
